S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

BMRN BioMarin Pharmaceutical Inc

65.947

-0.943 (-1.41%)

Last Updated: 05:05:40

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/12/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Charles G. Guyer

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Dec 2024 to Dec 2024

Click Here for more BioMarin Pharmaceutical Charts.

BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more BioMarin Pharmaceutical Charts.

BioMarin Pharmaceutical Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 4 December 2024 (4 weeks ago) • Edgar (US Regulatory)

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
Sunday 17 November 2024 (1 month ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 15 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 13 November 2024 (2 months ago) • Edgar (US Regulatory)

BioMarin to Participate in Three Upcoming Investor Conferences
Thursday 7 November 2024 (2 months ago) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 1 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 30 October 2024 (2 months ago) • Edgar (US Regulatory)

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
Wednesday 30 October 2024 (2 months ago) • PR Newswire (US)

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
Thursday 24 October 2024 (2 months ago) • GlobeNewswire Inc.

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET
Wednesday 16 October 2024 (2 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 2 October 2024 (3 months ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Wednesday 2 October 2024 (3 months ago) • Edgar (US Regulatory)

More BioMarin Pharmaceutical Inc News Articles

NEO Battery Materials

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions